SciBX: Science-Business eXchange Contents: June 14 2012, Volume 5 / Issue 24

TABLE OF CONTENTS June 14 2012, Volume 5 / Issue 24 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Endocrine/metabolic disease Genitourinary disease Infectious disease Neurology Various The Distillery: Techniques Assays and screens Drug delivery Drug platforms Relay Technology Management Real time business intelligence and data visualization for the Life Science Industry Trend monitoring and comparative asset analysis Click here for more information or to arrange a trial.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Crafting cancer combinations Joanne Kotz doi:10.1038/scibx.2012.617 Two groups have developed platforms that could improve the identification of cancer drug combinations. A UNC team is using chemical proteomics to rationally design kinase inhibitor combinations that block resistance pathways, whereas MIT researchers are screening for combinations that are synergistic when dosed sequentially. Full Text | PDF Targets and Mechanisms Top β testing adenosine receptor agonists Tim Fulmer doi:10.1038/scibx.2012.618 UCSF researchers have used a zebrafish screen to identify an adenosine receptor agonist that improved both β cell regeneration and glucose control in diabetic mice. The discovery could open up a new indication for a class of compounds that until now have been developed mainly for inflammatory and cardiovascular disorders. Full Text | PDF Tools Top Vaccines revisited Tracey Baas doi:10.1038/scibx.2012.619 An Oregon Health & Science University and Najít team has shown that hydrogen peroxide could be a better way to inactivate viral vaccines than conventional methods. Najít hopes to start a Phase I trial of an inactivated yellow fever virus vaccine in a few years. Full Text | PDF Sequencing MRD Lauren Martz doi:10.1038/scibx.2012.620 Fred Hutchinson researchers have developed a high throughput sequencing platform to detect minimal residual disease in patients with T cell acute lymphoblastic leukemia. The team has spun out Adaptive Biotechnologies Corp. to develop the technology. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top MicroRNA-23b (miR-23b) doi:10.1038/scibx.2012.621 Patient sample and mouse studies suggest agonizing miR-23b could help treat autoimmune diseases such as lupus, RA and MS. Full Text | PDF Cancer Top Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) doi:10.1038/scibx.2012.622 In vitro and mouse studies suggest iNOS inhibitors could help treat EGFRvIII-positive gliomas. Full Text | PDF Unknown doi:10.1038/scibx.2012.623 Cell culture studies suggest the lipid 2-hydroxyoleate (2OHOA) could help treat glioma. Full Text | PDF Dopamine receptor doi:10.1038/scibx.2012.624 Patient sample and cell culture studies suggest the dopamine receptor antagonist thioridazine could help treat cancer. Full Text | PDF Proline dehydrogenase 1 (PRODH; POX) doi:10.1038/scibx.2012.625 Mouse and cell culture studies suggest inhibiting PRODH could help treat hypoxia-driven tumors. Full Text | PDF EPH receptor A2 (EPHA2) doi:10.1038/scibx.2012.626 In vitro studies suggest EPHA2 could help prevent KS caused by KS-associated herpes virus (KSHV) infection. Full Text | PDF Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; LIR2) doi:10.1038/scibx.2012.627 Mouse and cell culture studies suggest inhibiting the interaction between angiopoietin-like proteins and LILRB2 could help treat leukemia. Full Text | PDF c-Met proto-oncogene (MET; HGFR) doi:10.1038/scibx.2012.628 In vitro and mouse studies suggest inhibiting exosome secretion could help treat cancers including melanoma. Full Text | PDF Androgen receptor (AR) doi:10.1038/scibx.2012.629 In vitro studies identified 1-(3-(2-chlorophenoxy)propyl)1H-indole-3-carbonitrile(CPIC) as an AR antagonist that could help treat prostate cancer. Full Text | PDF Endocrine/metabolic disease Top Adenosine A2A receptor (ADORA2A) doi:10.1038/scibx.2012.630 Zebrafish and mouse studies suggest adenosine receptor agonists could regenerate β cells and help treat type 1 diabetes. Full Text | PDF Apolipoprotein A-IV (APOA4) doi:10.1038/scibx.2012.631 Mouse studies suggest APOA4 could help treat type 2 diabetes. Full Text | PDF Glucocerebrosidase (GBA; GCase) doi:10.1038/scibx.2012.632 Mouse and in vitro studies identified small molecule chaperones of GCase that could help treat Gaucher's disease. Full Text | PDF Genitourinary disease Top Nuclear receptor coactivator 1 (NCOA1; SRC1) doi:10.1038/scibx.2012.633 Patient sample and mouse studies suggest inhibiting an SRC1 fragment could help treat endometriosis. Full Text | PDF Infectious disease Top α-Glycerophosphate oxidase (glpO) doi:10.1038/scibx.2012.634 Mouse and in vitro studies suggest vaccines against glpO could help prevent pneumococcal meningitis. Full Text | PDF Neurology Top Cyclophilin A (CYPA; PPIA) doi:10.1038/scibx.2012.635 Mouse studies suggest antagonizing PPIA could be useful for treating AD. Full Text | PDF Not applicable doi:10.1038/scibx.2012.636 Mouse studies suggest transplantation of inhibitory neuronal precursors to the spinal cord could help treat neuropathic pain. Full Text | PDF Various Top Not applicable doi:10.1038/scibx.2012.637 In vitro and mouse studies suggest the C-terminal domain of endostatin could help treat and prevent organ fibrosis. Full Text | PDF Distillery: Techniques Assays and screens Top Cell microarrays to identify drug-resistance pathways doi:10.1038/scibx.2012.638 Cell microarrays could be used to identify proteins and pathways mediating drug resistance in cancer. Full Text | PDF Drug delivery Top Nanoparticle-mediated delivery of wortmannin doi:10.1038/scibx.2012.639 A nanoparticle formulation of the pan–phosphoinositide 3-kinase (PI3K) inhibitor wortmannin could reduce the drug's hepatotoxicity. Full Text | PDF Drug platforms Top Deep sequencing for optimizing protein-based inhibitors of influenza A virus hemagglutinin doi:10.1038/scibx.2012.640 Deep sequencing could be useful for optimizing computationally designed protein-based inhibitors for influenza. Full Text | PDF Engineering IgG4 mutants with reduced heterogeneity and improved thermal stability doi:10.1038/scibx.2012.641 Engineered IgG4 mutants that have reduced heterogeneity and increased thermal stability could help improve the production of IgG4-based biologics. Full Text | PDF Low-density nanofiber scaffold to support cartilage repair doi:10.1038/scibx.2012.642 A low-density nanofiber scaffold could be useful for cartilage repair. Full Text | PDF Synthetic staphylococcal enterotoxin B (SEB)-neutralizing antibodies to prevent toxic shock doi:10.1038/scibx.2012.643 Synthetic SEB-neutralizing antibodies could help protect against toxic shock syndrome. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.